首页> 美国卫生研究院文献>Parasite Epidemiology and Control >Prevalence of bovine trypanosomosis and assessment of trypanocidal drug resistance in tsetse infested and non-tsetse infested areas of Northwest Ethiopia
【2h】

Prevalence of bovine trypanosomosis and assessment of trypanocidal drug resistance in tsetse infested and non-tsetse infested areas of Northwest Ethiopia

机译:埃塞俄比亚西北部采采蝇和非采采蝇的地区牛锥虫病流行率和锥虫杀虫剂耐药性评估

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

The Northwestern region of Ethiopia is affected by both tsetse and non-tsetse transmitted trypanosomosis with a significant impact on livestock productivity. The control of trypanosomosis in Ethiopia relies on either curative or prophylactic treatment of animals with diminazene aceturate (DA) or isometamidium chloride (ISM). In the present work; questionnaire survey, cross-sectional and experimental studies were carried out to; a) assess the utilization of trypanocidal drugs; b) determine the prevalence of bovine trypanosomosis and; c) assess the drug resistant problems respectively in Tsetse and non-tsetse infested areas on NW Ethiopia. A total of 100 respondents were included for the survey and the questionnaires focused on the drug utilization practices for the control of Trypanosomosis. Blood from cattle 640 (324 cattle tested in 2011, 316 cattle tested in 2012) and 795 (390 cattle tested in 2011, 405 cattle tested in 2012) were examined from tsetse infested and non-tsetse infested areas respectively using the buffy coat technique and thin blood smear for the detection of trypanosomes and measurement of packed cell volume (PCV). For the assessment of trypanocidal drug resistance three isolates, one from tsetse (TT) and two from non-tsetse (NT) areas were used on thirty six trypanosome naïve calves. The experimental animals were divided randomly into six groups of six animals (TT-ETBS2-DA, TT-ETBS2-ISM, NT-ETBD2-DA, NT-ETBD2-ISM, NT-ETBD3-DA and NT-ETBD3-ISM), which were infected with T. vivax isolated from a tsetse-infested or non-tsetse infested area with 2 × 106 trypanosomes from donor animals, and in each case treated with higher dose of DA or ISM. The results of the questionnaire survey showed trypanosomosis was a significant animal health constraint for 84% and 100% of the farmers questioned in non-tsetse and tsetse infested areas of Northwest Ethiopia respectively. Responses on trypanocidal drug utilization practices indicated that risk factors for the development of drug resistance are common and treatment failures are frequently seen. Accordingly, the majority of farmers in tsetse infested area get trypanocides from drug stores and unauthorized sources whereas those from non-tsetse area get from veterinary clinics. Moreover, treatment administration is mainly by animal health personnel and treatment frequency is a maximum of three times/year/animal in non-tsetse area whereas it is administered mainly by the farmers more than seven times/year/animal in tsetse infested area. The prevalence of trypanosomosis varied from 17.59% in 2011 to 25.0% in 2012 in tsetse infested areas with a significant (P = 0.023) difference. Similarly, in non-tsetse infested area the prevalence was varied from 3.85% in 2011 to 5.93% in 2012 without significant rise. Trypanosoma congolense (75%) was the most prevalent followed by T. vivax (20.58%) and mixed infections (4.41%) in tsetse infested area while in non-tsetse infested area only T. vivax was detected. The overall mean PCV in parasitaemic animals (20 ± 2.3 SD) was significantly (P < 0.001) lower than that of aparasitaemic animals (27 ± 4.3 SD). The assessment of trypanocidal drug resistance tests revealed one isolate of non-tsetse infested area against DA in group NT-ETBD2-DA is resistant to the higher dose used with 3 relapsing animals (50% relapses) in the group. Another two relapses were detected one against ISM for the isolate from tsetse infested area (TT-ETBS2-ISM) and one against DA for another isolate (NT-ETBD3-DA) from the non-tsetse area. In conclusion, trypanosomosis is widely prevalent in both study areas causing significant reduction in the mean PCV values. Farmers' trypanocidal utilization practices appear to pose risks of drug resistance problems. The in vivo drug resistance tests indicated the presence of resistant parasites with the higher dose against DA for NT-ETBD2 isolate and suspected resistance problems were detected against ISM and DA for TT-ETBS2 and NT-ETBD3 isolates respectively. Therefore, trypanosomosis is a major constraint in Northwest Ethiopia and drug resistance is a threat in the control of trypanosomosis in both study areas.
机译:采采蝇和非采采蝇传播的锥虫病都对埃塞俄比亚西北部地区产生了影响,这对畜牧生产力产生了重大影响。在埃塞俄比亚,锥虫病的控制依赖于用醋酸二咪唑(DA)或氯化异met胺(ISM)对动物的治疗或预防性治疗。在目前的工作中;进行问卷调查,横断面和实验研究; a)评估锥虫病药物的利用; b)确定牛锥虫病的患病率;以及c)分别评估埃塞俄比亚西北部采采蝇和非采采蝇感染地区的耐药性问题。总共包括100名受访者参加了此次调查,并且调查表的重点是控制锥虫病的药物使用方法。使用血沉棕黄层技术分别从采采蝇感染地区和非采采蝇感染地区检查了640头牛(2011年测试324头牛,2012年测试316头牛)和795头(2011年测试390头牛,2012年测试405头牛)的血液。薄血涂片,用于检测锥虫和包装细胞体积(PCV)。为了评估锥虫杀伤性,在三十六只锥虫幼体犊牛上使用了三种分离株,一种来自采采蝇(TT),另一种来自非采采蝇(NT)。将实验动物随机分为六组,每组六只动物(TT-ETBS2-DA,TT-ETBS2-ISM,NT-ETBD2-DA,NT-ETBD2-ISM,NT-ETBD3-DA和NT-ETBD3-ISM),感染了来自采采蝇或非采采蝇区域的间日疟原虫,并感染了来自供体动物的2×10 6 锥虫,并分别接受了较高剂量的DA或ISM处理。问卷调查的结果表明,锥虫病对埃塞俄比亚西北部非采采蝇和采采蝇疫区的84%和100%的被调查农民来说是严重的动物健康制约因素。对锥虫病药物利用实践的回应表明,耐药性发展的危险因素是常见的,而且治疗失败也很常见。因此,采采蝇疫区的大多数农民从药店和未经授权的来源获取锥虫病,而非采采蝇地区的农民则从兽医诊所获取。而且,在采采蝇处,治疗主要由动物卫生人员进行,在非采采蝇区,治疗频率最高为3次/年/动物,而在采采蝇疫区,主要由农民进行7次/年/动物以上。在采采蝇感染地区,锥虫病的患病率从2011年的17.59%到2012年的25.0%不等,差异有显着性(P = 0.023)。同样,在非采采蝇疫区,其患病率从2011年的3.85%变化到2012年的5.93%,而没有显着上升。在采采蝇感染地区,锥虫锥虫(75%)是最普遍的,其次是间日疟原虫(20.58%)和混合感染(4.41%),而在非采采蝇疫区仅检出间日疟原虫。寄生虫动物的总体平均PCV(20±2.3 SD)显着(P <0.001)低于寄生虫动物(27±4.3 SD)。锥虫杀伤性耐药性测试的评估显示,NT-ETBD2-DA组中一种针对DA的非采采蝇侵染区分离株对该组中3只复发动物的更高剂量耐药(复发率50%)。检测到另外两次复发,其中一个针对采采蝇疫区的分离株对抗ISM(TT-ETBS2-ISM),另一个针对非采采蝇区域的分离株针对NT(NT-ETBD3-DA)。总之,锥虫病在这两个研究领域中普遍流行,导致平均PCV值显着降低。农民的杀锥虫利用做法似乎带来了耐药性问题的风险。体内抗药性测试表明,对于NT-ETBD2分离株存在较高剂量的DA抗药性寄生虫,并且分别对TT-ETBS2和NT-ETBD3分离株检测到了针对ISM和DA的怀疑耐药性问题。因此,锥虫病是埃塞俄比亚西北部的主要限制因素,在这两个研究地区,耐药性是控制锥虫病的一个威胁。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号